Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy

K. Seborova, V. Hlavac, P. Holy, SS. Bjørklund, T. Fleischer, L. Rob, M. Hruda, J. Bouda, M. Mrhalova, MMKAO. Allah, P. Vodicka, O. Fiala, P. Soucek, VN. Kristensen, L. Vodickova, R. Vaclavikova

. 2022 ; 12 (-) : 1016958. [pub] 20221202

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22031132

Epithelial ovarian carcinoma (EOC) is known for high mortality due to diagnosis at advanced stages and frequent therapy resistance. Previous findings suggested that the DNA repair system is involved in the therapeutic response of cancer patients and DNA repair genes are promising targets for novel therapies. This study aimed to address complex inter-relations among gene expression levels, methylation profiles, and somatic mutations in DNA repair genes and EOC prognosis and therapy resistance status. We found significant associations of DUT expression with the presence of peritoneal metastases in EOC patients. The high-grade serous EOC subtype was enriched with TP53 mutations compared to other subtypes. Furthermore, somatic mutations in XPC and PRKDC were significantly associated with worse overall survival of EOC patients, and higher FAAP20 expression in platinum-resistant than platinum-sensitive patients was observed. We found higher methylation of RAD50 in platinum-resistant than in platinum-sensitive patients. Somatic mutations in BRCA1 and RAD9A were significantly associated with higher RBBP8 methylation in platinum-sensitive compared to platinum-resistant EOC patients. In conclusion, we discovered associations of several candidate genes from the DNA repair pathway with the prognosis and platinum resistance status of EOC patients, which deserve further validation as potential predictive biomarkers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22031132
003      
CZ-PrNML
005      
20230127131042.0
007      
ta
008      
230119s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.1016958 $2 doi
035    __
$a (PubMed)36531044
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Seborova, Karolina $u Toxicogenomics Unit, National Institute of Public Health in Prague, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
245    10
$a Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy / $c K. Seborova, V. Hlavac, P. Holy, SS. Bjørklund, T. Fleischer, L. Rob, M. Hruda, J. Bouda, M. Mrhalova, MMKAO. Allah, P. Vodicka, O. Fiala, P. Soucek, VN. Kristensen, L. Vodickova, R. Vaclavikova
520    9_
$a Epithelial ovarian carcinoma (EOC) is known for high mortality due to diagnosis at advanced stages and frequent therapy resistance. Previous findings suggested that the DNA repair system is involved in the therapeutic response of cancer patients and DNA repair genes are promising targets for novel therapies. This study aimed to address complex inter-relations among gene expression levels, methylation profiles, and somatic mutations in DNA repair genes and EOC prognosis and therapy resistance status. We found significant associations of DUT expression with the presence of peritoneal metastases in EOC patients. The high-grade serous EOC subtype was enriched with TP53 mutations compared to other subtypes. Furthermore, somatic mutations in XPC and PRKDC were significantly associated with worse overall survival of EOC patients, and higher FAAP20 expression in platinum-resistant than platinum-sensitive patients was observed. We found higher methylation of RAD50 in platinum-resistant than in platinum-sensitive patients. Somatic mutations in BRCA1 and RAD9A were significantly associated with higher RBBP8 methylation in platinum-sensitive compared to platinum-resistant EOC patients. In conclusion, we discovered associations of several candidate genes from the DNA repair pathway with the prognosis and platinum resistance status of EOC patients, which deserve further validation as potential predictive biomarkers.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hlavac, Viktor $u Toxicogenomics Unit, National Institute of Public Health in Prague, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Holy, Petr $u Toxicogenomics Unit, National Institute of Public Health in Prague, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Third Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Bjørklund, Sunniva S $u Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
700    1_
$a Fleischer, Thomas $u Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
700    1_
$a Rob, Lukas $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czechia
700    1_
$a Hruda, Martin $u Department of Gynecology and Obstetrics, Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czechia
700    1_
$a Bouda, Jiri $u Department of Gynecology and Obstetrics, University Hospital in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Mrhalova, Marcela $u Department of Pathology and Molecular Medicine, Motol University Hospital, Second Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Allah, Mohammad Moufaq Khatar Al Obeed $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Vodicka, Pavel $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czechia $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Fiala, Ondrej $u Department of Oncology and Radiotherapeutics, Faculty of Medicine in Pilsen and University Hospital, Charles University, Pilsen, Czechia $u Laboratory of Cancer Treatment and Tissue Regeneration, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Soucek, Pavel $u Toxicogenomics Unit, National Institute of Public Health in Prague, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
700    1_
$a Kristensen, Vessela N $u Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
700    1_
$a Vodickova, Ludmila $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia $u Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czechia $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Vaclavikova, Radka $u Toxicogenomics Unit, National Institute of Public Health in Prague, Prague, Czechia $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 1016958
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36531044 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230119 $b ABA008
991    __
$a 20230127131033 $b ABA008
999    __
$a ok $b bmc $g 1889378 $s 1182465
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2022 $b 12 $c - $d 1016958 $e 20221202 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20230119

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace